A KRAS-variant is a Biomarker of Poor Outcome, Platinum Chemotherapy Resistance and a Potential Target for Therapy in Ovarian Cancer

Germ-line variants in the 3′ untranslated region (3′UTR) of cancer genes disrupting microRNA (miRNA) regulation have recently been associated with cancer risk. A variant in the 3′UTR of the KRAS oncogene, referred to as the KRAS-variant, is associated with both cancer risk and altered tumor biology....

Descripción completa

Detalles Bibliográficos
Autores principales: Ratner, Elena S., Keane, Florence K., Lindner, Robert, Tassi, Renata A., Paranjape, Trupti, Glasgow, Michelle, Nallur, Sunitha, Deng, Yanhong, Lu, Lingeng, Steele, Linda, Sand, Sharon, Muller, Roman-Ulrich, Bignotti, Eliana, Bellone, Stefania, Boeke, Marta, Yao, Xiaopan, Pecorelli, Sergio, Ravaggi, Antonella, Katsaros, Dionyssios, Zelterman, Daniel, Cristea, Mihaela C., Yu, Herbert, Rutherford, Thomas J., Weitzel, Jeffrey N., Neuhausen, Susan L., Schwartz, Peter E., Slack, Frank J., Santin, Alessandro D., Weidhaas, Joanne B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2011
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3342446/
https://www.ncbi.nlm.nih.gov/pubmed/22139083
http://dx.doi.org/10.1038/onc.2011.539

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3342446/
https://www.ncbi.nlm.nih.gov/pubmed/22139083
http://dx.doi.org/10.1038/onc.2011.539

Ejemplares similares